FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements Journal Article
| Authors: | Bekaii-Saab, T. S.; Valle, J. W.; Van Cutsem, E.; Rimassa, L.; Furuse, J.; Ioka, T.; Melisi, D.; MacArulla, T.; Bridgewater, J.; Wasan, H.; Borad, M. J.; Abou-Alfa, G. K.; Jiang, P.; Lihou, C. F.; Zhen, H.; Asatiani, E.; Féliz, L.; Vogel, A. |
| Article Title: | FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements |
| Abstract: | FGFR2 rearrangements resulting in dysregulated signaling are drivers of cholangiocarcinoma (CCA) tumorigenesis, and occur almost exclusively in intrahepatic CCA. Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy and safety in a Phase II study of patients with previously treated locally advanced/metastatic CCA harboring FGFR2 fusions/rearrangements. We describe the study design of FIGHT-302, an open-label, randomized, active-controlled, multicenter, global, Phase III study comparing the efficacy and safety of first-line pemigatinib versus gemcitabine plus cisplatin in patients with advanced CCA with FGFR2 rearrangements (NCT03656536). The primary end point is progression-free survival; secondary end points are objective response rate, overall survival, duration of response, disease control rate, safety and quality of life. © 2020 Tanios Bekaii-Saab. |
| Keywords: | cholangiocarcinoma; fgfr; pemigatinib; incb054828 |
| Journal Title: | Future Oncology |
| Volume: | 16 |
| Issue: | 30 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2020-10-01 |
| Start Page: | 2385 |
| End Page: | 2399 |
| Language: | English |
| DOI: | 10.2217/fon-2020-0429 |
| PUBMED: | 32677452 |
| PROVIDER: | scopus |
| PMCID: | PMC9892961 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 December 2020 -- Source: Scopus |
